Bristol Myers Squibb expanded enterprise AI deployment by partnering with Anthropic to roll out Claude across global operations, aiming to accelerate multiple stages of drug discovery and development. The collaboration targets workflows beyond chat, including engineering productivity via Claude Code and agentic layers inside drug development tasks. BMS said it will evaluate Claude’s role in areas such as trial documentation automation, including draft clinical study reports and patient safety narratives. BMS also framed the effort as a way to unlock value trapped behind data silos by integrating Claude across research, clinical development, manufacturing, and commercial functions for more than 30,000 employees. The update matters for biotech implementation teams because it signals larger pharma is moving from pilot AI use cases toward embedded systems intended to support regulatory-facing deliverables and day-to-day execution.